Close

Antares, Watson Pharmaceuticals launch Gelnique 3% in US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder.

The product is available in a metered pump dispenser and is delivered transdermally, resulting in a low level of side effects such as dry mouth and constipation, common with orally administered OAB medications.

Watson Global Brands executive vice president Fred Wilkinson said, “The clinical trial demonstrated an early treatment effect versus placebo and improved efficacy over time.”

Gelnique 3%, approved by the FDA, was developed by Antares and was obtained through an exclusive licensing agreement by Watson.

Antares president and chief executive officer Paul Wotton said, “Watson’s experience and commitment to urology coupled with their well-established and knowledgeable commercial team makes them the perfect partner to market this next generation gel product for the treatment of overactive bladder.”

Latest stories

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back